Oncologia
Current management of newly diagnosed acute promyelocytic leukemia
Scritto da Annals of Oncology - current issue   
Oncologia

The management of acute promyelocytic leukemia (APL) has considerably evolved during the past two decades. The advent of all-trans retinoic acid (ATRA) and its inclusion in combinatorial regimens with anthracycline chemotherapy has provide ... ...

 
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
Scritto da Annals of Oncology - current issue   
Oncologia

The tumor microenvironment (TME) is an integral part of cancer. Recognition of the essential nature of the TME in cancer evolution has led to a shift from a tumor cell-centered view of cancer development to the concept of a complex tumor ecosyste ... ...

 
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Scritto da Annals of Oncology - current issue   
Oncologia

The emergence of programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1)–targeted therapy has demonstrated the importance of the PD-L1 : PD-1 interaction in inhibiting anticancer T-cell immunity in multiple human cancers, generating dur ... ...

 
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Scritto da Annals of Oncology - current issue   
OncologiaBackground

Data on CA-125 as a predictor of disease progression (PD) in ovarian cancer come predominantly from patients with platinum-sensitive disease receiving chemotherapy alone. We assessed concordance between CA-125-defined and ... ...

 
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment
Scritto da Annals of Oncology - current issue   
OncologiaBackground

Clinical and pathological parameters of patients with epithelial ovarian cancer (EOC) do not thoroughly predict patients' outcome. Despite the good outcome of stage I EOC compared with that of stages III and IV, the risk ... ...

 
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lap
Scritto da Annals of Oncology - current issue   
OncologiaBackground

The predictive value of PIK3CA mutations in HER2 positive (HER2+) breast cancer treated with neoadjuvant anti-HER2 and chemotherapy has been reported, but the power for subgroup analyses was lacking.

 
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
Scritto da Annals of Oncology - current issue   
OncologiaBackground

Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic bre ... ...

 
Inizio Prec. 1 2 3 4 5 6 7 8 9 10 Succ. > Fine >>

Pag 2 di 3690